{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiaijnmygd2zyz5hhx7wyxbrrtfk5o2lphiorw5y6veo2ladbvtfsi",
    "uri": "at://did:plc:izotgtw5czjnuqtpcldjnkjh/app.bsky.feed.post/3mluslatkjzg2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifwfjhj5nw7nrw7mzsce4n7q2m7l5l4p6hhanqyki5xmgspdiufvm"
    },
    "mimeType": "image/jpeg",
    "size": 132883
  },
  "path": "/common-blood-pressure-drug-supercharges-cancer-treatment-in-surprising-new-study/",
  "publishedAt": "2026-05-15T02:48:32.000Z",
  "site": "https://scitechdaily.com",
  "tags": [
    "Health",
    "Blood Pressure",
    "Cancer",
    "Dartmouth College",
    "Immunotherapy",
    "Oncology",
    "Pharmaceuticals"
  ],
  "textContent": "A common blood pressure drug may help a major class of cancer therapies work far better than expected. A widely prescribed blood pressure drug may have an unexpected second life as a cancer therapy booster. Researchers at Dartmouth Cancer Center (DCC) have discovered that telmisartan, an FDA-approved medication commonly used to treat hypertension, can significantly [...]",
  "title": "Common Blood Pressure Drug Supercharges Cancer Treatment in Surprising New Study"
}